Patients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based on the results of a 27-gene panel, following findings from a meta-analysis.
In women with HER2 (ERBB2)-positive breast cancer brain metastases, combination therapy with pyrotinib and capecitabine elicited an intracranial response in a phase 2 trial.
No Benefit Seen With Everolimus in Early Breast Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.